
    
      This is a single arm clinical trial in subjects with advanced solid tumor receiving multiple
      doses of YH001 intravenously (IV). YH001 will be administered (IV) in 19-37 patients with
      advanced solid tumors. An accelerated titration method followed by a traditional 3+3 dose
      escalation scheme will be utilized to determine MTD(maximum tolerated dose) and/or
      RP2D(recommended phase 2 dose). Patients will be dosed at Dose A, Dose B, Dose C, Dose D,
      Dose E, Dose F and Dose G every 3 weeks (Q3W) for 15 weeks (5 cycles).
    
  